Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04428671 · ClinicalTrials.gov registry record · Phase 1

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

A Phase 1 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, sponsored by Emory University.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT04428671 is a Phase 1 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 20 participants, below the 63-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04428671, a Phase 1 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cemiplimab before surgery may improve risk of the cancer returning in patients with high risk cutaneous squamous cell cancer.

Conditions Studied

Metastatic Skin Squamous Cell Carcinoma Recurrent Skin Squamous Cell Carcinoma

Interventions

  • RADIATION Radiation Therapy
  • BIOLOGICAL Cemiplimab
  • PROCEDURE Therapeutic Conventional Surgery

Study Locations (1)

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-05-15
Est. Completion 2031-10-01
Phase Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04428671

The ClinicalTrials.gov registry entry for NCT04428671 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (68% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.

NCT04428671 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT04428671 about?

NCT04428671 is a clinical study titled "Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer". This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of t...

What is the current status of trial NCT04428671?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-05-15. Estimated completion is 2031-10-01.

What conditions does trial NCT04428671 study?

This clinical trial studies the following conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04428671?

The interventions under investigation include: Radiation Therapy (RADIATION), Cemiplimab (BIOLOGICAL), Therapeutic Conventional Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT04428671?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04428671 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Skin Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Skin Squamous Cell Carcinoma

All registered trials for this condition

Recurrent Skin Squamous Cell Carcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.